Sangui BioTech:

• Increase in sales of 170% in the first three quarters of the year
• Operating gain in the first three quarters of the year

Hamburg, May 06, 2025:
In the first nine months of fiscal year 2025 (to 30/06/2025) Sangui BioTech International Inc. achieved revenues from royalty income of USD 256,006. In the same period of the previous year the comparable revenue amounted to USD 94,755. Due to higher revenues of the wound spray Granulox, the resulting royalty income in the first nine-month period of the year increased by 170% compared to the same period of the previous year.

Operating expenses increased USD 18,203 or 19% to USD 115,484 during the first nine months of the year. As a result of the above factors, the nine-month operating result increased USD 143,045 from an operating loss of USD 2,523 to an operating gain of USD 140.522.

Despite a higher exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting exchange rate loss from the valuation of loans denominated in EURO, a positive nine-month result of USD 101,949 occurred. Compared to the previous year, in which a loss of USD 12,854 had to be recorded in the comparable period, the nine-month result improved by USD 114,803.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the pink marketplace operated by OTC Markets Group Inc. Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

---